1. Home
  2. KE vs XERS Comparison

KE vs XERS Comparison

Compare KE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KE
  • XERS
  • Stock Information
  • Founded
  • KE 1961
  • XERS 2005
  • Country
  • KE United States
  • XERS United States
  • Employees
  • KE N/A
  • XERS N/A
  • Industry
  • KE Electrical Products
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • KE Technology
  • XERS Health Care
  • Exchange
  • KE Nasdaq
  • XERS Nasdaq
  • Market Cap
  • KE 442.5M
  • XERS 526.3M
  • IPO Year
  • KE N/A
  • XERS 2018
  • Fundamental
  • Price
  • KE $13.06
  • XERS $4.37
  • Analyst Decision
  • KE Buy
  • XERS Strong Buy
  • Analyst Count
  • KE 5
  • XERS 6
  • Target Price
  • KE $22.20
  • XERS $5.92
  • AVG Volume (30 Days)
  • KE 134.0K
  • XERS 4.5M
  • Earning Date
  • KE 05-06-2025
  • XERS 03-06-2025
  • Dividend Yield
  • KE N/A
  • XERS N/A
  • EPS Growth
  • KE N/A
  • XERS N/A
  • EPS
  • KE 0.32
  • XERS N/A
  • Revenue
  • KE $1,586,842,000.00
  • XERS $203,070,000.00
  • Revenue This Year
  • KE N/A
  • XERS $31.75
  • Revenue Next Year
  • KE N/A
  • XERS $21.09
  • P/E Ratio
  • KE $43.23
  • XERS N/A
  • Revenue Growth
  • KE N/A
  • XERS 23.89
  • 52 Week Low
  • KE $13.70
  • XERS $1.69
  • 52 Week High
  • KE $24.45
  • XERS $6.07
  • Technical
  • Relative Strength Index (RSI)
  • KE 16.42
  • XERS 43.57
  • Support Level
  • KE $16.00
  • XERS $4.96
  • Resistance Level
  • KE $17.18
  • XERS $6.07
  • Average True Range (ATR)
  • KE 0.63
  • XERS 0.29
  • MACD
  • KE -0.36
  • XERS -0.14
  • Stochastic Oscillator
  • KE 5.28
  • XERS 0.69

About KE Kimball Electronics Inc.

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Share on Social Networks: